Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Ingenia Therapeutics Goes Public on KOSDAQ to Accelerate Pipeline of Next-Generation Vascular Antibody TherapeuticsWATERTOWN, Mass., August 18, 2026--Ingenia Therapeutics, a clinical-stage biotechnology company pioneering next-generation vascular-targeted therapies, announced today that its shares have begun trading on the KOSDAQ market. The IPO marks a significant milestone as the company accelerates the development and global commercialization of its proprietary vascular stabilization pipeline.
- InnoCare Announces Approval of Head-to-Head Registrational Phase III Trial of Mesutoclax with Azacitidine versus Venetoclax with Azacitidine in Treatment-Naive AML in ChinaThe registrational Phase III study of the mesutoclax regime versus venetoclax regime in elderly or unfit patients with TN AML has been approved in China.
- Regeneron Pharmaceuticals, Inc. Notice of September 14, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP Before Application DeadlineInvestors who lost money in REGN after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
- CAPR Stock Alert: Capricor Therapeutics, Inc. (CAPR) Reports Q2 Earnings Amid Ongoing Securities Class Action Lawsuit – Hagens BermanInvestors who lost money in CAPR after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
- Robbins LLPRobbins LLP Urges SPRY Stockholders Who Lost Money Investing in ARS Pharmaceuticals Inc. to Contact the Firm for Information About Leading the Class Action LawsuitRobbins LLP reminds shareholders that a securities class action has been filed on behalf of all investors who purchased or otherwise acquired ARS Pharmaceuticals Inc. (NASDAQ: SPRY) securities between March 9, 2026 and June 24, 2026 (the "Class...
- AARD Investor Notice: Hagens Berman Alerts Investors in Aardvark Therapeutics (NASDAQ: AARD) to Filing of Securities Class ActionInvestors who lost money in AARD after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
- Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights– Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets –
- Robbins LLPAARD Stockholder Notice: Robbins LLP Reminds Investors of the Class Action Lawsuit Against Aardvark Therapeutics, Inc.Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) (a) common stock pursuant to the Company's...
- Trade Healthcare, Finance, and Consumer Giants on ZoomexVictoria,Seychelles, Aug. 17, 2026 -- Zoomex has expanded its Stock Perpetuals lineup with twelve new USDT-margined contracts, giving traders 24/7 exposure to some of the most closely watched names in U.S. equities. UnitedHealth Group (UNH), General Electric (GE), JPMorgan Chase (JPM), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Amgen (AMGN), Walmart (WMT), Coca-Cola (KO), PepsiCo (PEP), Mastercard (MA), PayPal Holdings (PYPL), and Berkshire Hathaway Class B (BRK.B) are now live for long and short positions, with no traditional market hours required.
- Robbins LLPDid You Lose Money Investing in Replimune Group, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About their Rights Against REPLShareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Replimune Group, Inc. (NASDAQ: REPL) securities between October 20, 2025 and April 10, 2026 ("Class Period"). Replimune purports to be a clinical-stage biotechnology company focused on novel oncolytic immunotherapies. According to the complaint, the Company's lead product...
- Sagimet Biosciences Inc.Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that, in connection with the hiring of 3 employees, the Compensation Committee of Sagimet’s Board of Directors approved that an inducement grant of 260,700 stock options in aggregate to purchase shares of the Company’s Series A common stock be granted on August 17, 2026 to the newly hired employees.
- IQVIAIQVIA Ranked No. 1 Pharmaceutical Technology Provider by Everest GroupCompanies: IQVIA Holdings, Inc.Everest GroupRESEARCH TRIANGLE PARK, N.C., August 17, 2026--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced that it has been ranked No. 1 in Everest Group’s "Top 50™ Pharmaceutical Technology Providers" report for 2026.